Invasive Ductal Cancer

What is invasive ductal cancer?

Invasive ductal cancer occurs when malignant epithelial cells break through the basement membrane of the milk ducts and invade the surrounding breast tissue. This is the most common type of invasive breast cancer, accounting for about 70% to 85% of invasive breast cancer diagnoses. It is also sometimes called infiltrating duct cancer because it can spread into nearby tissues and potentially reach nearby lymph nodes or distant organs. Screening mammography can detect suspicious masses, architectural distortion, or calcifications before a physical lump becomes noticeable.

Early detection significantly improves clinical outcomes by allowing treatment before the cancer has spread. Clinicians use standardized screening to monitor people without symptoms, especially those at higher risk. Because this malignancy can behave aggressively, its identification triggers a comprehensive staging process to determine the extent of disease and the tumor’s molecular characteristics.

What causes invasive ductal cancer?

There is no single cause of invasive ductal cancer. Advancing age, a first-degree family history of breast cancer, and inherited mutations in genes such as BRCA1 or BRCA2 increase the risk. Factors such as prolonged estrogen exposure, alcohol consumption, obesity after menopause, and prior chest radiation can also contribute to risk. Many tumors are hormone receptor-positive, which is important because it helps guide treatment.

The transition from a localized lesion to an invasive cancer involves loss of normal cell control, changes in cell-to-cell adhesion, and the ability of malignant cells to invade surrounding breast tissue. Identifying the tumor’s receptor status and molecular subtype helps oncology teams select therapies that target the pathways fueling the cancer’s growth.

What are the signs and symptoms of invasive ductal cancer?

The most frequent clinical presentation is a new breast lump. The lump is often firm, painless, and irregular, although some cancers can be tender or less clearly defined. Other findings may include localized skin dimpling, nipple discharge, nipple retraction, swelling, or a lump in the underarm area. Stage 1 invasive ductal breast cancer is often small and may cause no physical symptoms, making mammographic detection especially important.

As the disease progresses to Stage 2 invasive ductal breast cancer, the tumor may be larger or may involve a small number of nearby lymph nodes. Stage 3 invasive ductal breast cancer is more advanced and may involve more extensive regional lymph node disease, skin involvement, or chest wall involvement. People may also notice peau d’orange, a skin change where the breast surface resembles an orange peel due to lymphatic obstruction. On mammography, invasive ductal breast cancer often appears as an irregular or spiculated mass, sometimes with associated calcifications.

How is invasive ductal cancer diagnosed?

Diagnostic evaluation begins with mammography and targeted ultrasound to characterize suspected masses or microcalcifications. Breast MRI may provide additional information in selected cases, such as dense breast tissue, high-risk screening, or suspected multifocal disease. Core needle biopsy confirms the diagnosis of invasive ductal cancer and allows for essential receptor profiling. This profiling determines whether the tumor expresses estrogen receptors, progesterone receptors, or HER2, which helps guide treatment.

Lymph nodes are evaluated with imaging when indicated, and many early-stage cases are staged with sentinel lymph node biopsy. Clinicians use a TNM-based classification system to categorize tumor size, lymph node involvement, and distant metastasis. These findings correspond to specific invasive ductal breast cancer stages outlined by oncology guidelines. Correctly localizing the disease through these diagnostic steps ensures that management aligns with the anatomical and biological extent of the cancer.

How is invasive ductal cancer treated?

The invasive ductal breast cancer treatment plan may include surgery, radiation therapy, and systemic therapy to reduce the risk of recurrence. Initial management usually involves breast-conserving surgery followed by radiation or mastectomy for more extensive disease. Sentinel lymph node biopsy results and other nodal findings guide whether additional axillary treatment is needed. Systemic therapy depends on the tumor’s biology; hormone receptor-positive tumors often receive endocrine therapy, HER2-positive tumors receive HER2-targeted therapy, and some tumors require chemotherapy or immunotherapy.

Neoadjuvant therapy may be used to shrink larger tumors before surgery and to show how the cancer responds to treatment. This approach is particularly relevant for many triple-negative and HER2-positive cancers, as well as some larger or node-positive tumors. Radiation therapy may treat the remaining breast tissue, chest wall, or regional lymph nodes, depending on the surgical approach and cancer stage. Treatment often requires a multidisciplinary team to optimize the person’s long-term health.

What are the most important facts to know about invasive ductal cancer?

• Invasive ductal cancer starts in the ductal epithelium and is the most common type of invasive breast cancer found through routine screening.
• Risk factors such as BRCA mutations, estrogen exposure, family history, alcohol use, obesity after menopause, and prior chest radiation can increase the risk of invasive ductal breast cancer.
• Stage 1 invasive ductal breast cancer is often small and may not be palpable, which highlights the importance of mammography.
• The appearance of palpable axillary nodes, a larger breast mass, or subtle skin changes can occur with Stage 2 invasive ductal breast cancer or more advanced disease.
• Skin changes such as peau d’orange, chest wall involvement, or more extensive lymph node disease can occur in stage 3 invasive ductal breast cancer.
• Diagnosis combines mammography, ultrasound, selective MRI use, biopsy, receptor testing, and staging to identify the invasive ductal breast cancer stages and guide management.
• Comprehensive invasive ductal breast cancer treatment may include surgery, radiation therapy, endocrine therapy, chemotherapy, HER2-targeted therapy, or immunotherapy, depending on the tumor subtype and stage.
• Current invasive ductal cancer survival rates are usually discussed using overall breast cancer stage data: 5-year relative survival is about 100% for localized breast cancer and about 34% for distant metastatic breast cancer.
• The prognosis for infiltrating ductal breast cancer depends on the cancer stage, grade, receptor status, molecular subtype, response to treatment, and the person’s overall health.